On or around March 2006 the Board received information that the Respondent purchased a quatity of Botulinum Neurotoxin Type A which is manufactured by TRI, as an alternative to Botox, which is produced by Allergan Inc., and the only FDA approved and licensed Botulinum Toxin Type A medical product in the U.S.

The Respondent admits that he had purchased a total of 4 vials of Botulinum Toxin Type A in July and December, 2003. He admits that he injected himself and his wife with the Botulinum Toxin Type A purchased from TRI. He could not confirm that any of his other patients were injected. The Respondent did not make or keep appropriate medical records for those patients injected.

The Board voted on November 13, 2007 to issue a consent agreement for findings of fact, conclusions of law and order for decree of censure.